Please assess the completion status of the following clinical trial:

Trial Title: Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Type 2 diabetes on diet and exercise therapy or monotherapy with metformin, insulin secretagogue (including SFU, non-SFU, and dipeptidyl peptidase IV (DPP-4) inhibitors), alpha-glucosidase inhibitors, or bile acid sequestrants (dosed once per day such that study drug can be administered ≥ 4 hours prior to sequestrant); or a combination of up to two of these at maximal dose. Dosing must be stable for 8 weeks prior to screening. Participant must have been diagnosed with T2D at least 8 weeks before screening.~2. FPG ≤ 225 mg/dL and HbA1c≥7% and ≤ 9.5% at screening.~3. Age ≥18 and \<75~4. Women of childbearing potential agree to use an appropriate contraceptive method (hormonal, IUD, or diaphragm)~Exclusion Criteria:~1. No prior participation in Stage I of TINSAL-T2D ; exception: a participant who failed screening for HbA1c in Stage I will be allowed to re-screen for Stage II.~2. Type 1 diabetes and/or history of ketoacidosis determined by medical history~3. History of severe diabetic neuropathy including autonomic neuropathy, gastroparesis or lower limb ulceration or amputation~4. History of long-term therapy with insulin (\>30 days) within the last year~5. Therapy with rosiglitazone (Avandia) or pioglitazone (Actos), alone or in combination in the previous 6 months; or exendin-4 (Byetta), alone or in combination in the previous 3 months~6. Pregnancy or lactation~7. Patients requiring oral corticosteroids within 3 months or recurrent continuous oral corticosteroid treatment (more than 2 weeks)~8. Use of weight loss drugs \[e.g., Xenical (orlistat), Meridia (sibutramine), Acutrim (phenylpropanol-amine), or similar over-the-counter medications\] within 3 months of screening or intentional weight loss of ≥ 10 lbs in the previous 6 months~9. Surgery within 30 days prior to screening~10. Serum creatinine \>1.4 for women and \>1.5 for men or eGFR \<60 \[possible chronic kidney disease stage 3 or greater calculated using the Modification of Diet in Renal Disease (MDRD) equation~11. History of chronic liver disease including hepatitis B or C~12. History of peptic ulcer or endoscopy demonstrated gastritis~13. History of acquired immune deficiency syndrome or human immunodeficiency virus (HIV)~14. History of malignancy, except participants who have been disease-free for greater than 10 years, or whose only malignancy has been basal or squamous cell skin carcinoma~15. New York Heart Association Class III or IV cardiac status or hospitalization for congestive heart failure~16. History of unstable angina, myocardial infarction, cerebrovascular accident, transient ischemic attack or any revascularization within 6 months~17. Uncontrolled hypertension (defined as systolic blood pressure \>150 mmHg or diastolic blood pressure \>95 mmHg on three or more assessments on more than one day). If on blood pressure medications, dosing should be stable for 2 weeks prior to randomization.~18. History of drug or alcohol abuse, or current weekly alcohol consumption \>10 units/week (1 unit = 1 beer, 1 glass of wine, 1 mixed DCCktail containing 1 ounce of alcohol)~19. Hemoglobin \<12 g/dL (males), \<10 g/dL (females) at screening\*~20. Platelets \<100,000 cu mm at screening~21. AST (SGOT) \>2.50 x ULN or ALT (SGPT) \>2.50 x ULN at screening~22. Total Bilirubin \>1.50 x ULN at screening~23. Triglycerides (TG) \>500 mg/dL at screening~24. Poor mental function or any other reason to expect patient difficulty in complying with the requirements of the study~25. Previous allergy to aspirin~26. Chronic or continuous use (daily for more than 7 days) of nonsteroidal anti-inflammatory drugs within the preceding 2 months~27. Use of warfarin (Coumadin), clopidogrel (Plavix), dipyridamole (Persantine), heparin or other anticoagulants~28. Use of probenecid (Benemid, probalan), sulfinpyrazone (Anturane) or other uricosuric agents~29. Macroalbuminuria, defined as spot urine protein \>300 mcg/mg Cr at screening~30. Pre-existing chronic tinnitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Salsalate, 3.5 g/d orally, divided dosing
- 2 (Type: PLACEBO_COMPARATOR): Salsalate Placebo, orally, divided dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete